美多巴联合普拉克索治疗帕金森病的效果

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Medopa combined with Pramipexole on cognitive function and quality of life(QOL)in patients with Parkinson′s disease(PD).Methods From January 2016 to January 2018,126 patients with PD admitted in our hospital were selected as subjects.They were randomly divided into Medodopa group (n=63)and Pramipexole group(n=63).Medopa group was treated with Medopa,while the Pramipexole group was treated with Pramipexole on the basis of above treatment.The therapeutic effect were compared between the two groups.Results After treatment,the score of Parkinson′s scale Ⅲ (UPDRSⅢ)was significantly lower than that before treatment,the Montreal cognitive scale(MoCA)and simple mental state evaluation scale(MMSE)were significantly lower than those before treatment,whlie the score of UPDRSⅢin Pramipexole group was significantly lower than that in Medopa group,the scores of MoCA and MMSE were significantly higher than those in Pramipexole group,the differences were statistically significant(P＜0.05).After treatment,two groups of patients with levels of serum glutathione (GSH)and glutathione peroxidase(GSH-Px)were significantly higher than those before treatment,the level of reactive oxygen species (ROS)was lower than that before treatment,and the levels of GSH and GSH-Px in the Pramipexole group were significantly higher than those in Medopa group,the ROS level was significantly lower than that in Medopa group,the differences were statistically significant(P＜0.05).The physical,psychological,independence,social relationship and environment of the Pramipexole group were all higher than those of the Medopa group,the differences were statistically significant(P＜0.05).The total incidence of adverse reactions in Pramipexole group was 6.35%,and it was 12.70%in the Medopa grou,and the difference was not statistically significant(P＞0.05).Conclusion The clinical symptoms of PD patients can be effectively alleviated by the combination of Medopa and Pramipexole.It can improve its cognitive function and quality of life,clinical application is safe and effective.

Key words： Medopa Pramipexole Parkinson&prime s disease Cognitive function Quality of life

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Lei

Cite this article:

WANG Lei. Efficacy of Medopa combined with Pramipexole in the treatment of Parkinson′s disease[J]. 中国当代医药, 2018, 25(9): 93-96.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I9/93

[1]	任洁明，王万华.联合应用美多巴与普拉克索治疗帕金森病的临床疗效[J].中国临床研究，2016，29（11）：1482-1484.
[2]	廖华印，陈文明，胡琼力，等.应用姿势平衡仪及三维步态分析系统评价帕金森病患者康复疗效的临床研究[J].山西医药杂志，2017，46（8）：914-918.
[3]	吴艳，杜娟，任义胜，等.美多芭联合恩他卡朋对中晚期帕金森患者的临床疗效研究[J].药学与临床研究，2017，25（2）：121-123.
[4]	孙慧丽.普拉克索联合美多芭治疗帕金森病效果观察[J].山东医药，2017，57（42）：83-85.
[5]	李雪，姜立刚.多巴胺受体激动剂在帕金森病治疗中的剂量与疗效关系探讨[J].国际老年医学杂志，2016，37（4）：145-149.
[6]	刘焯霖.帕金森病的诊断标准[J].中华神经外科杂志，2002，18（1）：65.
[7]	中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南（第3版）[J].中华神经科杂志，2014，47（6）：428-433.
[8]	李金虹，钱进，富欣然，等.帕金森病患者焦虑及抑郁与其他症状关系的研究[J].中国全科医学，2016，19（17）：2002-2006.
[9]	汤海艳，王军，魏其林，等.MoCA和MMSE评估老年帕金森病患者认知障碍的分析[J].中风与神经疾病杂志，2013，30（8）：719-723.
[10]	Saracchi E，Fermi S，Brighina L.Emerging candidate biomarkers for Parkinson′s disease：a review[J].Aging Dis，2014，5（1）：27-34.
[11]	宋彬彬，段智慧，张雅敏.普拉克索对帕金森病患者血清胱抑素C、抗氧化指标及脑源性神经生长因子水平的影响[J].中国生化药物杂志，2016，36（6）：70-72.
[12]	张沁，黄江，刘春风，等.帕金森病患者视网膜结构及功能的研究进展[J].中华神经科杂志，2017，50（1）：67-71.
[13]	刘佳，段春礼，杨慧.帕金森病发病机制与治疗研究进展[J].生理科学进展，2015，46（3）：163-169.
[14]	黄晓勇，薛刘军.美多芭、普拉克索联合治疗帕金森病患者的效果及对血清代谢组学的影响[J].医学临床研究，2016，33（12）：2478-2480.
[15]	吴艳，杜娟，任义胜.美多芭联合恩他卡朋治疗对帕金森病患者血浆同型半胱氨酸水平的影响[J].临床神经病学杂志，2016，29（5）：333-335.
[16]	尤汉生，毛秀琴，石俊，等.美多巴联合普拉克索对老年帕金森病患者非运动症状的疗效分析[J].国际精神病学杂志，2017，44（4）：649-651.
[17]	魏新丽，郭彦谷，陈孛玉，等.活化星形胶质细胞参与多巴胺神经元氧化应激损伤的研究进展[J].神经解剖学杂志，2017，33（3）：363-366.
[18]	吴艳，王小姗，张丽，等.美多芭对帕金森病患者抗氧化效应的研究[J].临床神经病学杂志，2015，28（6）：431-433.